The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Olema Pharmaceuticals Inc shares valued at $1,727,370 were purchased by Bain Capital Life Sciences Inv on Jan 08 ’25. At $5.76 per share, Bain Capital Life Sciences Inv acquired 300,000 shares. The insider’s holdings grew to 7,800,000 shares worth approximately $31.67 million following the completion of this transaction.
Also, Graham G. Walmsley sold 700,761 shares, netting a total of over 4,730,137 in proceeds. Following the sale of shares at $6.75 each, the insider now holds 0 shares.
Before that, Logos Opportunities Fund I LP had added 700,761 shares to its account. In a trade valued at $4,730,137, the Affiliate bought Olema Pharmaceuticals Inc shares for $6.75 each.
As published in their initiating research note from Goldman on April 02, 2024, Olema Pharmaceuticals Inc [OLMA] has been a Buy and the price target has been revised to $24. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in late January. As of July 21, 2023, Oppenheimer has initiated its “an Outperform” rating for OLMA. Earlier on May 05, 2023, CapitalOne initiated its rating. Their recommendation was “an Overweight” for OLMA stock.
Analyzing OLMA Stock Performance
On last trading session,, Olema Pharmaceuticals Inc [NASDAQ: OLMA] plunged -0.49% to $4.06. The stock’s lowest price that day was $3.92, but it reached a high of $4.2 in the same session. During the last five days, there has been a drop of approximately -3.56%. Over the course of the year, Olema Pharmaceuticals Inc shares have dropped approximately -30.36%.
Support And Resistance Levels for Olema Pharmaceuticals Inc (OLMA)
RSI (Relative Strength Index) is 39.25 on the 14-day chart, showing neutral technical sentiment.
Is Olema Pharmaceuticals Inc subject to short interest?
Stocks of Olema Pharmaceuticals Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.87 million shares to 6.3 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 5.43 million shares. A jump of 13.73% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.1 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.1.
Which companies own the most shares of Olema Pharmaceuticals Inc (OLMA)?
In terms of Olema Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 28.5 in the next 12 months, up nearly 598.53% from the previous closing price of $4.08. Analysts anticipate Olema Pharmaceuticals Inc stock to reach 30 by 2025, with the lowest price target being 27. In spite of this, 3 analysts ranked Olema Pharmaceuticals Inc stock as Buy at the end of 2025. On February 22, 2023, Credit Suisse assigned a price target of “an Outperform” to the stock and initiated coverage with a $12.
